Tenax Therapeutics, Inc. downgraded to Hold ahead of Aug 2026 phase 3 TNX-103 data in PH-HFpEF; weigh 6MWD odds, downside, ...
Details Strategic Actions Taken by the Board to Advance the Company’s Pipeline and Drive Value CreationVaxart’s Purpose-Built Board Brings the ...
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company") is a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial ...
Late-breaking presentation at SID and featured presentation at the ATS Respiratory Innovation Summit highlight KT-621 BroADen Phase 1b clinical data and potential across Type 2 inflammatory diseases ...
Even when a presentation doesn’t go to plan, the experience can offer lessons about content, preparation and reflections on effective ways to communicate your research to an audience So, there I was, ...
Together, these data underscore the continued advancement of Immatics’ PRAME franchise and its focus on developing novel immunotherapies for patients with solid tumors. Full abstracts will be ...
LEXINGTON, Mass.--(BUSINESS WIRE)--TRIANA Biomedicines, Inc. (TRIANA), a leading biopharmaceutical company focused on advancing a target-first and proximity-first molecular glue discovery platform to ...
TRIANA Biomedicines Announces Oral Presentation of TRI-611 and Additional Poster Presentations at the American Association for Cancer Research Annual Meeting 2026 TRIANA Biomedicines, Inc. (TRIANA), a ...
All students in the oral presentation must submit at least one slide to accompany their presentation. All presentation slides must be submitted in PowerPoint (PPT) format. Slides should not include ...
Individual presentation times are noted in your formal invitation and on the Speaker Center website. A question-and-answer panel will be held for all session participants at the end of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results